What is Zacks Research's Forecast for TMO Q2 Earnings?

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Equities researchers at Zacks Research boosted their Q2 2025 earnings estimates for shares of Thermo Fisher Scientific in a note issued to investors on Wednesday, July 9th. Zacks Research analyst R. Department now expects that the medical research company will post earnings per share of $5.20 for the quarter, up from their previous forecast of $5.19. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific's Q2 2027 earnings at $7.08 EPS.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same period last year, the company posted $5.11 EPS.

Several other analysts also recently commented on TMO. Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Argus lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, UBS Group downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $500.00 to $460.00 in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $600.30.

Thermo Fisher Scientific Stock Up 1.0%

TMO stock traded up $4.29 during mid-day trading on Friday, hitting $435.02. 2,511,384 shares of the company were exchanged, compared to its average volume of 1,995,412. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm has a market cap of $164.22 billion, a P/E ratio of 25.51, a P/E/G ratio of 2.29 and a beta of 0.77. The firm's 50 day simple moving average is $409.16 and its 200 day simple moving average is $477.24. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently modified their holdings of the business. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $25,000. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after acquiring an additional 33 shares in the last quarter. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $30,000. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific during the first quarter worth about $30,000. Finally, Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific during the first quarter worth about $31,000. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.